DUBLIN, Nov. 10, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/gzwsdl/global_antibody) has announced the addition of the "Global Antibody Partnering 2010-2015: Deal trends, players and financials" report to their offering.
The Global Oncology Partnering 2010-2015 report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest oncology agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all oncology partnering deals announced since 2010 including financial terms where available including over 3,500 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Global Oncology Partnering 2010-2015 includes:
- Trends in oncology dealmaking in the biopharma industry since 2010
- Analysis of oncology deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 3,500 oncology deal records
- The leading oncology deals by value since 2010
In Global Oncology Partnering 2010-2015, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in antibody dealmaking
Chapter 3 - Leading antibody deals
Chapter 4 - Big pharma antibody deals
Chapter 5 - Big Biotech antibody deals
Chapter 6 - Antibody dealmaking directory with contract documents
Chapter 7- Antibody dealmaking by antibody technology type
Chapter 8 - Antibody partnering resource center
For more information visit http://www.researchandmarkets.com/research/gzwsdl/global_antibody
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets